Jack_Chen_qy
2021-07-19
Nice
UPDATE 1-Taiwan approves Medigen's COVID-19 vaccine candidate
免责声明:上述内容仅代表发帖人个人观点,不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP,发表看法
APP内打开
发表看法
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":171965577,"tweetId":"171965577","gmtCreate":1626702993999,"gmtModify":1633924803927,"author":{"id":3576899111877903,"idStr":"3576899111877903","authorId":3576899111877903,"authorIdStr":"3576899111877903","name":"Jack_Chen_qy","avatar":"https://static.tigerbbs.com/d7857d3bb380dd24f38771faa0cbd29c","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":3,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":1,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Nice</p></body></html>","htmlText":"<html><head></head><body><p>Nice</p></body></html>","text":"Nice","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/171965577","repostId":2152763920,"repostType":2,"repost":{"id":"2152763920","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1626677157,"share":"https://www.laohu8.com/m/news/2152763920?lang=&edition=full","pubTime":"2021-07-19 14:45","market":"us","language":"en","title":"UPDATE 1-Taiwan approves Medigen's COVID-19 vaccine candidate","url":"https://stock-news.laohu8.com/highlight/detail?id=2152763920","media":"Reuters","summary":"(Recasts, adds details) TAIPEI, July 19 (Reuters) - Taiwan's government on Monday approved the use","content":"<html><body><p>(Recasts, adds details)</p><p> TAIPEI, July 19 (Reuters) - Taiwan's government on Monday approved the use and production of Medigen Vaccine Biologics Corp's COVID-19 vaccine candidate, a major step in the island's plans to develop its own vaccines to protect against the coronavirus.</p><p> Taiwan-based Medigen said last month it was seeking a speedy emergency use authorisation, or EUA, from the government for its vaccine candidate after safely completing Phase II trials.</p><p> Developing its own vaccine has been a major goal of Taiwan's government, though it also has ordered some 20 million shots from Moderna Inc , AstraZeneca and the COVAX global sharing scheme.</p><p> The health ministry said in clinical trials in Taiwan the antibodies created by Medigen's vaccine candidate have been proven to be \"no worse than\" those created by AstraZeneca <a href=\"https://laohu8.com/S/PLC\">PLC</a></p><p> vaccines, and that there were no major safety concerns.</p><p> The ministry added that Medigen had to present a monthly report on safety for the vaccine candidate, MVC-COV1901, which is designed for people aged over 20, who will get two shots 28 days apart.</p><p> Health Minister Chen Shih-chung told reporters that with the EUA approved, it would now take some time for the company to ramp up its production.</p><p> \"There should be a small amount of supply available in August,\" he added.</p><p> The recombinant protein vaccine has been developed in collaboration with the National Institutes of Health in the United States.</p><p> Taiwan's government in May signed deals with Medigen, and another firm developing a domestic vaccine, UBI Pharma</p><p> , for five million doses each, and has agreements for another five million each, for a total of 20 million shots. </p><p> The EUA for UBI's vaccine candidate is still pending.</p><p> Taiwan has massively ramped up its vaccination programme in the last month following the donation of almost 6 million vaccine doses from Japan and the United States and the gradual arrival of vaccines directly ordered from manufacturers.</p><p> Around 20% of Taiwan's 23.5 million people have received at least <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the two-shot vaccine regimen.</p><p> (Reporting by Ben Blanchard and Yimou Lee; Editing by Christopher Cushing and Michael Perry)</p><p>((ben.blanchard@thomsonreuters.com;))</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>UPDATE 1-Taiwan approves Medigen's COVID-19 vaccine candidate</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUPDATE 1-Taiwan approves Medigen's COVID-19 vaccine candidate\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-07-19 14:45</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p>(Recasts, adds details)</p><p> TAIPEI, July 19 (Reuters) - Taiwan's government on Monday approved the use and production of Medigen Vaccine Biologics Corp's COVID-19 vaccine candidate, a major step in the island's plans to develop its own vaccines to protect against the coronavirus.</p><p> Taiwan-based Medigen said last month it was seeking a speedy emergency use authorisation, or EUA, from the government for its vaccine candidate after safely completing Phase II trials.</p><p> Developing its own vaccine has been a major goal of Taiwan's government, though it also has ordered some 20 million shots from Moderna Inc , AstraZeneca and the COVAX global sharing scheme.</p><p> The health ministry said in clinical trials in Taiwan the antibodies created by Medigen's vaccine candidate have been proven to be \"no worse than\" those created by AstraZeneca <a href=\"https://laohu8.com/S/PLC\">PLC</a></p><p> vaccines, and that there were no major safety concerns.</p><p> The ministry added that Medigen had to present a monthly report on safety for the vaccine candidate, MVC-COV1901, which is designed for people aged over 20, who will get two shots 28 days apart.</p><p> Health Minister Chen Shih-chung told reporters that with the EUA approved, it would now take some time for the company to ramp up its production.</p><p> \"There should be a small amount of supply available in August,\" he added.</p><p> The recombinant protein vaccine has been developed in collaboration with the National Institutes of Health in the United States.</p><p> Taiwan's government in May signed deals with Medigen, and another firm developing a domestic vaccine, UBI Pharma</p><p> , for five million doses each, and has agreements for another five million each, for a total of 20 million shots. </p><p> The EUA for UBI's vaccine candidate is still pending.</p><p> Taiwan has massively ramped up its vaccination programme in the last month following the donation of almost 6 million vaccine doses from Japan and the United States and the gradual arrival of vaccines directly ordered from manufacturers.</p><p> Around 20% of Taiwan's 23.5 million people have received at least <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the two-shot vaccine regimen.</p><p> (Reporting by Ben Blanchard and Yimou Lee; Editing by Christopher Cushing and Michael Perry)</p><p>((ben.blanchard@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"http://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2152763920","content_text":"(Recasts, adds details) TAIPEI, July 19 (Reuters) - Taiwan's government on Monday approved the use and production of Medigen Vaccine Biologics Corp's COVID-19 vaccine candidate, a major step in the island's plans to develop its own vaccines to protect against the coronavirus. Taiwan-based Medigen said last month it was seeking a speedy emergency use authorisation, or EUA, from the government for its vaccine candidate after safely completing Phase II trials. Developing its own vaccine has been a major goal of Taiwan's government, though it also has ordered some 20 million shots from Moderna Inc , AstraZeneca and the COVAX global sharing scheme. The health ministry said in clinical trials in Taiwan the antibodies created by Medigen's vaccine candidate have been proven to be \"no worse than\" those created by AstraZeneca PLC vaccines, and that there were no major safety concerns. The ministry added that Medigen had to present a monthly report on safety for the vaccine candidate, MVC-COV1901, which is designed for people aged over 20, who will get two shots 28 days apart. Health Minister Chen Shih-chung told reporters that with the EUA approved, it would now take some time for the company to ramp up its production. \"There should be a small amount of supply available in August,\" he added. The recombinant protein vaccine has been developed in collaboration with the National Institutes of Health in the United States. Taiwan's government in May signed deals with Medigen, and another firm developing a domestic vaccine, UBI Pharma , for five million doses each, and has agreements for another five million each, for a total of 20 million shots. The EUA for UBI's vaccine candidate is still pending. Taiwan has massively ramped up its vaccination programme in the last month following the donation of almost 6 million vaccine doses from Japan and the United States and the gradual arrival of vaccines directly ordered from manufacturers. Around 20% of Taiwan's 23.5 million people have received at least one of the two-shot vaccine regimen. (Reporting by Ben Blanchard and Yimou Lee; Editing by Christopher Cushing and Michael Perry)((ben.blanchard@thomsonreuters.com;))","news_type":1},"isVote":1,"tweetType":1,"viewCount":37,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":4,"xxTargetLangEnum":"ORIG"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/171965577"}
精彩评论